Wenting Du
Immunology and Microbiology · University of Michigan
Publications
229
Citations
2,600
Est. group size
~37
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~11 · 12% small-team papers (≤3 authors) · across 34 venues
- Abstract 210: Bivalent nanoparticle vaccine elicits cross-protective antibody against oncogenic herpesviruses.
Cancer Research · 2026
- Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S5 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Figure S3 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Material S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Tables S1-S15 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Supplementary Material S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026
- Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab
Modern Pathology · 2025
- <i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
Journal of Clinical Oncology · 2025
- Regulation of inflammatory responses: Harnessing the Ruan Mai Jian targeting of EphA2/ephrinA1 pathway to enhance atherosclerosis amelioration
Phytomedicine · 2025
- WITHDRAWN: 470P Neoadjuvant cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: Supplementary biomarker analyses from CABIN trial
Annals of Oncology · 2025
- Cancer Research×12
- bioRxiv (Cold Spring Harbor Laboratory)×7
- Stem Cell Research×4
- JCI Insight×3
- Journal of Clinical Oncology×3
- Jay Li
Immunology and Microbiology · University of Michigan
- Katelyn L. Donahue
Immunology and Microbiology · University of Michigan
- Ahmed M. Elhossiny
Immunology and Microbiology · University of Michigan
- Carlos E. Espinoza
Immunology and Microbiology · University of Michigan
- Kristee Brown
Immunology and Microbiology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile